Using physiologically‐based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet
Abstract A combination of olanzapine and samidorphan (OLZ/SAM) was recently approved by the US Food and Drug Administration for treatment of patients with schizophrenia or bipolar I disorder. The effects of moderate hepatic impairment on the pharmacokinetics (PKs) of olanzapine and samidorphan after...
Main Authors: | Lei Sun, Zoe Barter, Lisa vonMoltke, Karen Rowland Yeo |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-09-01
|
Series: | CPT: Pharmacometrics & Systems Pharmacology |
Online Access: | https://doi.org/10.1002/psp4.12675 |
Similar Items
-
Physiologically‐Based Pharmacokinetic Modeling for Predicting Drug Interactions of a Combination of Olanzapine and Samidorphan
by: Lei Sun, et al.
Published: (2020-02-01) -
Effect of hepatic and renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination as a bilayer tablet
by: Sun L, et al.
Published: (2019-08-01) -
Characterization of the Pharmacokinetics of Samidorphan in Healthy Volunteers: Absolute Bioavailability and the Effect of Food and Age
by: Vipul Kumar, et al.
Published: (2019-08-01) -
A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine
by: Manit Srisurapanont, et al.
Published: (2021-04-01) -
Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers
by: Bajorunas, D., et al.
Published: (2022)